# PDUFA dates January 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-01

> 71 FDA catalysts are dated in January 2025, including 4 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in January 2025?

PDUFA dates in January 2025: Ryoncil (ryoncil, MESO) on January 7, 2025; Revascor (revascor, MESO) on January 7, 2025; Tab-cel (tabelecleucel, ATRA) on January 15, 2025; AXS-07 (AXSM) on January 31, 2025. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-01)

Source: Press release filed with the SEC (EX-99), accession 0001345099-24-000079, https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm (retrieved 2026-11-12). Last confirmed 2025-10-28. Cite: https://sec-api.dev/fda-calendar/2025-01#answer

## PDUFA dates in January 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| January 7, 2025 | MESOBLAST LTD | MESO | Ryoncil (ryoncil) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm) |
| January 7, 2025 | MESOBLAST LTD | MESO | Revascor (revascor) | congenital heart disease, adults with low ejection fraction heart failure | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm) |
| January 15, 2025 | Atara Biotherapeutics, Inc. | ATRA | Tab-cel (tabelecleucel) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm) |
| January 31, 2025 | Axsome Therapeutics, Inc. | AXSM | AXS-07 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm) |

## All catalysts in January 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 2, 2025 | [Deramiocel NDA/BLA submission](https://sec-api.dev/pdufa/deramiocel) | CAPR | diagnosed with Duchenne muscular dystrophy | completed | "On January 2, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that it has completed the submission of its Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000155837025000010/capr-20250102x8k.htm)) |
| January 2, 2025 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000009/a8kex991earningsrelease25q2.htm)) |
| January 2, 2025 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "SAN DIEGO, CA - January 8, 2025 - Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323925000002/mrvi-pressreleaseq42024pre.htm)) |
| January 3, 2025 | [CID-103 trial start](https://sec-api.dev/pdufa/cid-103) | CASIF |  | completed | "- First patient dosed in Phase 1/2 clinical trial in ITP on January 3, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962738/000110465925029652/tm2510656d1_ex99-1.htm)) |
| January 6, 2025 | [ZYCUBO (CUTX-101) NDA/BLA acceptance](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease | completed | "On January 6, 2025, we announced that the FDA accepted the NDA for CUTX-101 for priority review, and on January 16, 2025, we disclosed the extension of the PDUFA target action date to September 30, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1429260/000155837025004160/fbio-20241231x10k.htm)) |
| January 6, 2025 | [OCS-05 topline data readout](https://sec-api.dev/pdufa/ocs-05) | OCS |  | completed, met | "ZUG, Switzerland, January 6, 2025 - Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results with OCS-05 in the Phase 2 ACUITY trial, which met the primary endpoint of safety and achieved statistical significance on several key efficacy-based secondary endpoints." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953530/000095017025002044/ocs-ex99_1.htm)) |
| January 7, 2025 | [Ryoncil (ryoncil) PDUFA date](https://sec-api.dev/pdufa/ryoncil) | MESO |  | completed, approved | "19 m e s o b l a s t Mesoblast resubmitted its Biologics License Application (BLA) to FDA for approval of RYONCIL on July 8, 2024 and anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| January 7, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. announces preliminary Fourth quarter 2024 results and provides business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea022695701ex99-1_cormedix.htm)) |
| January 7, 2025 | [Revascor (revascor) PDUFA date](https://sec-api.dev/pdufa/revascor) | MESO | congenital heart disease, adults with low ejection fraction heart failure | scheduled | "PDUFA date Jan 7th 2025 Study in adult patients for label extension to follow pediatric approval Program Key Objectives REVASCOR Heart Failure 2 3 CLBP Phase 3 trial actively enrolling at multiple sites across the U.S. The 300-patient randomized, placebo-controlled trial has a 12-month primary endpoint of pain reduction Heart failure in children with congenital heart disease, adults with low ejection fraction heart failure (HFrEF) Preparing for accelerated approval filing" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| January 7, 2025 | [NEREUSTM (tradipitant) NDA/BLA acceptance](https://sec-api.dev/pdufa/tradipitant) | VNDA |  | completed | "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUSTM in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm)) |
| January 8, 2025 | [GS-0321 trial start](https://sec-api.dev/pdufa/com503) | CGEN |  | completed | "HOLON, ISRAEL - January 8, 2025 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891325000053/exhibit_99-1.htm)) |
| January 8, 2025 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed, positive | "On January 8, 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and on August 19, 2025, we announced positive top-line results from the trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1607678/000119312525247059/vktx-20250930.htm)) |
| January 10, 2025 | [NextCure, Inc. trial start](https://sec-api.dev/companies/nxtc/catalysts) | NXTC | cancer, today | completed | "On January 10, 2025, NextCure, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/nxtc-20250110x8k.htm)) |
| January 10, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "The Company plans to report its fourth quarter and full year 2024 financial results in late February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110xex99d1.htm)) |
| January 10, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira expects to report its complete financial results for the fourth quarter and full-year 2024, along with the company's financial guidance, later in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/pcrx-2024revenuepressrelea.htm)) |
| January 10, 2025 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | FDMT |  | completed, positive | "On January 10, 2025, the Company reported positive topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in DME and alignment with the U.S. Food and Drug Administration ("FDA") on registrational pathway for 4D-150 in DME." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm)) |
| January 10, 2025 | [ARV-102 trial start](https://sec-api.dev/pdufa/arv-102) | ARVN | Parkinson's disease | completed | "The Company also announced that it recently initiated a Phase 1 clinical trial with PROTAC leucine-rich repeat kinase 2 ("LRRK2") protein degrader ARV-102 in patients with Parkinson's disease and that, in 2025, the Company plans to:" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/arvn-20250110.htm)) |
| January 10, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore will report its final and complete fourth-quarter and full-year 2024 financial results in late February 2025, and the actual results could be different from these preliminary unaudited financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_ex99-1.htm)) |
| January 12, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm)) |
| January 12, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis will report complete fourth quarter and full-year 2024 financial results and provide a business update on Tuesday, February 25, 2025 after the U.S. financial markets close." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/pressreleaseex991pre-earni.htm)) |
| January 12, 2025 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm)) |
| January 13, 2025 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/mxct-20250113xex99d1.htm)) |
| January 13, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Fourth quarter and full-year 2024 financial results are preliminary, unaudited, subject to adjustment, and provided as an approximation in advance of the Companys announcement of complete financial results in February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000119312525004939/d925380dex991.htm)) |
| January 13, 2025 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/tm252898d1_ex99-1.htm)) |
| January 13, 2025 | [KRRO-110 trial start](https://sec-api.dev/pdufa/krro-110) | KRRO |  | completed | "On January 13, 2025, Korro Bio, Inc. issued a press release announcing that it has dosed the first participants in its REWRITE Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and provided a pipeline update." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/d915237d8k.htm)) |
| January 13, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "The Company expects to announce complete full year 2024 financial results and provide a corporate update in February." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm)) |
| January 13, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "This announcement is not a comprehensive statement of Axsome's financial results and is subject to completion of Axsome's financial closing procedures." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/axsm-ex99_1.htm)) |
| January 13, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "The Company expects to report its final and complete fourth quarter and full-year 2024 financial results in late February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348dex991.htm)) |
| January 13, 2025 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta will report its final and complete fourth quarter and full -year 2024 financial results in late February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/d900352dex991.htm)) |
| January 14, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000114036125001060/ef20041599_ex99-1.htm)) |
| January 14, 2025 | [Investigator trial start](https://sec-api.dev/pdufa/investigator) | CNTX |  | completed | "On January 14, 2025, Context Therapeutics Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Company's Phase 1 clinical trial evaluating CTIM-76." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/cntx-20250114.htm)) |
| January 15, 2025 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| January 15, 2025 | [Omvoh (mirikizumab-mrkz) label expansion decision](https://sec-api.dev/pdufa/mirikizumab-mrkz) | LLY |  | completed, approved | "BLA761279 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250115, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OMVOH (MIRIKIZUMAB-MRKZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761279%22)) |
| January 15, 2025 | [Tab-cel (tabelecleucel) complete response letter (CRL)](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 01/15/2025 for BL 125745 to Atara Biotherapeutics, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125745_20250115.pdf%22)) |
| January 16, 2025 | [EBVALLOTM (ebvallotm) complete response letter (CRL)](https://sec-api.dev/pdufa/ebvallotm) | ATRA |  | completed, complete response letter | "The clinical hold was directly linked to GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the Complete Response Letter (CRL) for EBVALLOTM that was announced on January 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721dex991.htm)) |
| January 16, 2025 | [Calquence (acalabrutinib) label expansion decision](https://sec-api.dev/pdufa/acalabrutinib) | AZN |  | completed, approved | "NDA210259 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name ASTRAZENECA; product CALQUENCE (ACALABRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210259%22)) |
| January 16, 2025 | [Vectibix® (panitumumab) label expansion decision](https://sec-api.dev/pdufa/panitumumab) | AMGN |  | completed, approved | "BLA125147 SUPPL-213 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name AMGEN; product VECTIBIX (PANITUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125147%22)) |
| January 16, 2025 | [LUMYKRAS™ (sotorasib) label expansion decision](https://sec-api.dev/pdufa/sotorasib) | AMGN |  | completed, approved | "NDA214665 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name AMGEN INC; product LUMAKRAS (SOTORASIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214665%22)) |
| January 17, 2025 | [REDEMPLO (plozasiran) NDA/BLA acceptance](https://sec-api.dev/pdufa/plozasiran) | ARWR |  | completed | "On information and belief, Arrowhead filed a New Drug Application ("NDA") seeking to market plozasiran (25mg) for the treatment of FCS, and FDA accepted that application on January 17, 2025.21 44." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000010/a991complaint.htm)) |
| January 17, 2025 | [Spravato (esketamine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/esketamine) | JNJ |  | completed, approved | "NDA211243 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20250117, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product SPRAVATO (ESKETAMINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211243%22)) |
| January 17, 2025 | [Nda219112 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219112) | PFE |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219112_20250117.pdf%22)) |
| January 21, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2024 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2024, which is anticipated to occur in early March 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000006/ex991012125.htm)) |
| January 21, 2025 | [JNJ-1900 trial start](https://sec-api.dev/pdufa/jnj-1900) | NBTX | Stage 3 Unresectable Non-Small Cell Lung Cancer | completed | "PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the ''Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1760854/000117184325000325/exh_991.htm)) |
| January 21, 2025 | [Vusolimogene oderparepvec NDA/BLA acceptance](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed | "Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925005291/tm254066d1_ex99-1.htm)) |
| January 21, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "11 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025002290/valnevapr22-1x25.htm)) |
| January 22, 2025 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "ABBOTT PARK, Ill., Jan. 22, 2025 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/abt-2024q4xexhibitx991.htm)) |
| January 23, 2025 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide topline data readout](https://sec-api.dev/pdufa/ihl-42x) | IXHL |  | completed, positive | "2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of Obstructive Sleep Apnea (OSA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390025005700/ea022831301ex99-1_incannex.htm)) |
| January 23, 2025 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250123, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| January 27, 2025 | [IPH4502 trial start](https://sec-api.dev/pdufa/iph4502) | IPHA | advanced solid tumors known to express Nectin-4 | completed | "•On January 27, 2025, the Company announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000159859925000075/inpha-20250630_d2.htm)) |
| January 27, 2025 | [VERU INC. topline data readout](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed, positive | "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774925015330/veru20250331_10q.htm)) |
| January 27, 2025 | [Enobosarm topline data readout](https://sec-api.dev/pdufa/enobosarm) | VERU |  | completed, positive | "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study which is a multicenter, double-blind, placebo-controlled, randomized, dose-finding QUALITY clinical trial designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight older (>60 years of age) patients receiving semaglutide (Wegovy)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/d935703dex991.htm)) |
| January 27, 2025 | [Aria® (golimumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/golimumab) | ALVO | with inflammatory conditions | completed | "REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm)) |
| January 27, 2025 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "LINCOLN, Nebraska, January 27, 2025 — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774925001928/ex_770300.htm)) |
| January 27, 2025 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | VERU |  | completed, positive | "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774925003734/veru20241231_10q.htm)) |
| January 27, 2025 | [GTB-3650 trial start](https://sec-api.dev/pdufa/gtb-3650) | GTBP | Hematologic Malignancies | completed | "January 27, 2025, GT Biopharma, Inc. (the "Company") issued a press release announcing that the first patient was dosed in the Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315225003707/form8-k.htm)) |
| January 27, 2025 | [Cyramza (ramucirumab) label expansion decision](https://sec-api.dev/pdufa/ramucirumab) | LLY |  | completed, approved | "BLA125477 SUPPL-48 (Efficacy): submission_status AP, submission_status_date 20250127, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product CYRAMZA (RAMUCIRUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125477%22)) |
| January 28, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/nrix-20250128xexx991.htm)) |
| January 28, 2025 | [SAB Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/sabs/catalysts) | SABS |  | completed, positive | "MIAMI, January 28, 2025 - SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833214/000095017025009474/sabs-ex99_1.htm)) |
| January 28, 2025 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| January 28, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-172 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| January 28, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA209637 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22)) |
| January 29, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm)) |
| January 30, 2025 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE |  | completed, positive | "On 30 January 2025, Alterity announced the positive topline results led by robust clinical efficacy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025037102/ea024013201ex99-1_alterity.htm)) |
| January 30, 2025 | [SYMBRAVO® (meloxicam-rizatriptan) FDA approval](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM | central nervous system | completed, approved | "On January 30, 2025, Axsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO® for the acute treatment of migraine with or without aura in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-20250130.htm)) |
| January 30, 2025 | [Tectonic Therapeutic, Inc. interim data readout](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed, positive | "WATERTOWN, Mass., January 30, 2025 (GLOBE NEWSWIRE)  Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/d817477dex992.htm)) |
| January 30, 2025 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/February 5, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000155837025000639/tech-20250130xex99d1.htm)) |
| January 30, 2025 | [Symbravo (meloxicam; rizatriptan benzoate) FDA approval](https://sec-api.dev/pdufa/meloxicam-rizatriptan-benzoate) | AXSM |  | completed, approved | "NDA215431 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20250130, review_priority STANDARD; sponsor_name AXSOME; product SYMBRAVO (MELOXICAM; RIZATRIPTAN BENZOATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215431%22)) |
| January 30, 2025 | [JOURNAVX (suzetrigine) FDA approval](https://sec-api.dev/pdufa/suzetrigine) | VRTX | To treat moderate to severe acute painPress Release | completed, approved | "Journavx \| suzetrigine \| 1/30/2025 \| To treat moderate to severe acute painPress Release Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| January 31, 2025 | [AXS-07 PDUFA date](https://sec-api.dev/pdufa/axs-07) | AXSM |  | scheduled | "NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm)) |
| January 31, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/abbv-20241231xexhibit991.htm)) |
| January 31, 2025 | [PAXLOVID® (nirmatrelvir-ritonavir) label expansion decision](https://sec-api.dev/pdufa/nirmatrelvir-ritonavir) | PFE |  | completed, approved | "NDA217188 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250131, review_priority PRIORITY; sponsor_name PFIZER; product PAXLOVID (COPACKAGED) (NIRMATRELVIR; RITONAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217188%22)) |

Other months: https://sec-api.dev/fda-calendar/2024-12 , https://sec-api.dev/fda-calendar/2025-02. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates January 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-01

```bibtex
@misc{secapidev_fda_calendar_2025_01_20261116,
  title        = {PDUFA dates January 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-01}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_01_20261116","title":"PDUFA dates January 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-01","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
